MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00134-023-07178-6

Медицинская библиотека · Intensive care medicine · 2023

Magnesium sulphate in patients with thrombotic thrombocytopenic purpura (MAGMAT): a randomised, double-blind, superiority trial.

Zafrani Lara, Canet Emmanuel, Walter-Petrich Anouk, Joly-Laffargue Bérangère, Veyradier Agnès, Faguer Stanislas, Bigé Naïke, Calvet Laure, Mayaux Julien, Grangé Steven, Rafat Cédric, Poulain Coralie, Klouche Kada, Perez Pierre, Pène Frédéric, Pichereau Claire, Duceau Baptiste, Mariotte Eric, Chevret Sylvie, Azoulay Elie

Equivalence TrialСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

PURPOSE: Studies have suggested benefits from magnesium sulphate in thrombotic thrombocytopenic purpura (TTP). We aimed to measure the effects of magnesium sulphate supplementation on TTP recovery.

METHODS

In this multicenter, randomised, double-blind, controlled, superiority study, we enrolled adults with a clinical diagnosis of TTP. Patients were randomly allocated to receive magnesium sulphate (6 g intravenously followed by a continuous infusion of 6 g/24 h for 3 days) or placebo, in addition to the standard treatment. The primary outcome was the median time to platelet normalisation (defined as a platelet count ≥ 150 G/L). Efficacy and safety were assessed by intention-to-treat.

RESULTS

Overall, we enrolled 74 participants, including one who withdrew his/her consent. Seventy-three patients were further analyzed, 35 (48%) allocated to magnesium sulphate and 38 (52%) to placebo. The median time to platelet normalisation was 4 days (95% confidence interval [CI], 3-4) in the magnesium sulphate group and 4 days (95% CI 3-5) in the placebo group. The cause-specific hazard ratio of response was 0.93 (95% CI 0.58-1.48, p = 0.75). The number of patients with ≥ 1 serious adverse reactions was similar in the two groups. By day 90, four patients in the magnesium sulphate group and two patients in the placebo group had died (p = 0.42). The most frequent adverse event was low blood pressure occurring in 34% in the magnesium sulphate group and 29% in the placebo group (p = 0.80).

CONCLUSION

Among patients with TTP, the addition of magnesium sulphate to the standard of care did not result in a significant improvement in time to platelet normalisation.

Для цитирования: Zafrani Lara, Canet Emmanuel, Walter-Petrich Anouk, Joly-Laffargue Bérangère, Veyradier Agnès, Faguer Stanislas, Bigé Naïke, Calvet Laure, Mayaux Julien, Grangé Steven, Rafat Cédric, Poulain Coralie, Klouche Kada, Perez Pierre, Pène Frédéric, Pichereau Claire, Duceau Baptiste, Mariotte Eric, Chevret Sylvie, Azoulay Elie. Magnesium sulphate in patients with thrombotic thrombocytopenic purpura (MAGMAT): a randomised, double-blind, superiority trial.. Intensive care medicine. 2023. DOI: 10.1007/s00134-023-07178-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.